Learn the latest in lipid lowering therapy in this extensive discussion with Dr. Paul S. Jellinger, MD, MACE, Professor of Medicine at the University of Miami and Chair of the writing committee for the American Association of Clinical Endocrinologists (AACE) 2017 Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease (CVD). Topics include ezetimibe, PCSK9, FOURIER trial, statin myopathy, CoQ10, fish oil, fibrates and more. For a more basic discussion of dyslipidemia check out episode #10.

Full show notes are available at http://thecurbsiders.com/podcast

Join our newsletter mailing list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com.

Time Stamps

00:00 Intro

03:10 Rapid fire questions

08:15 Dyslipidemia defined

10:26 Classifying dyslipidemia

13:21 Diagnosing Familial Hypercholesterolemia

17:48 A difficult lipid case discussed

22:40 Lp (a), Apo B and LDL particle concentration

28:40 What labs to order

31:31 ACC/AHA versus other risk scores

38:21 IMPROVE-IT

41:35 Non-statin medications discussed

45:05 Hypertriglyceridemia fibrates and fish oil

48:25 How often to check the lipid panel

49:58 Statin Myopathy and CoQ10

54:17 FOURIER, PCSK9 and very low LDLs

59:43 Extreme risk category discussed

62:34 Is plaque regression possible?

64:12 Take home points

67:08 Outro

Tags: assistant, care, cholesterol, doctor, education family, fish oil, foam, foamed, health, hospitalist, hospital, internal, internist, ldl, lipid, medicine, medical, myopathy, nurse, pcsk9, physician, practitioner, primary, statin, resident, student

#37: Lipids, PCSK9, and ezetimibe: Lower is better.

The Curbsiders Internal Medicine Podcast